ImmuCell (ImmuCell) GF Value : $6.90 (As of May. 14, 2024)

View and export this data going back to 1995. Start your Free Trial

What is ImmuCell GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-14), ImmuCell's share price is $5.4765. ImmuCell's GF Value is $6.90. Therefore, ImmuCell's Price-to-GF-Value for today is 0.79.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes ImmuCell is Modestly Undervalued.

ImmuCell (NAS:ICCC) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

ImmuCell's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	5.4765	/	6.90
	=	0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell GF Value Related Terms

Thank you for viewing the detailed overview of ImmuCell's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuCell (ImmuCell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

IUL:Germany

Address

56 Evergreen Drive, Portland, ME, USA, 04103

Website

https://www.immucell.com

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.

Executives

Bryan K. Gathagan	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen	director	C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin	other: See Explanation of Responses	C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin	other: See Explanation of Responses	310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb	director, officer: Vice President and CSO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams	officer: Vice Pres. of Mfg Operations	C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild	director, 10 percent owner	C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham	director, officer: President and CEO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde	other: Director of Sales and Marketin	56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce	director	56 EVERGREEN DRIVE, PORTLAND ME 04103